Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;8(2):126-7.
doi: 10.4103/0973-6247.137453.

Prevalence of platelet reactive antibodies in patient's refractory to platelet transfusions

Nitin Agarwal  1 , Kabita Chatterjee  1 , Alok Sen  2 , Praveen Kumar  3
Affiliations
Free PMC article

Prevalence of platelet reactive antibodies in patient's refractory to platelet transfusions

Nitin Agarwal et al. Asian J Transfus Sci. 2014 Jul.
Free PMC article

Abstract

Introduction & aims: Though platelet transfusions have greatly reduced the incidence of major haemorrhagic complications associated with the management of haematological and oncological disorders, refractoriness to infused platelets becomes a major clinical problem for many of these patients.

Materials and methods: The present study was done to determine the percentage of platelet alloimmunisation due to platelet-reactive antibodies in 340 patients with hematologic or oncologic diseases who had received multiple transfusions (> 10) of blood and blood components and showed platelet refractoriness in 1-hour post transfusion sample.

Results: Platelet-reactive antibodies were detected in the sera of 127 out of 340 patients (37.35%) who received multiple transfusions (> 10) and showed platelet refractoriness.

Conclusion: Platelet-reactive antibodies appear to be an important cause of platelet refractoriness in patients of acute leukaemia, aplastic anaemia, NHL, MDS and multiple myeloma receiving multiple platelet transfusions. Platelet refractoriness in patients of ITP and chronic leukaemia appears to be due to other causes and not due to platelet-reactive antibodies.

Keywords: Platelet alloimmunization; platelet immunofluorescent test; refractoriness.

PubMed Disclaimer

Conflict of interest statement

Conflicting Interest: None declared

Similar articles

See all similar articles

Cited by

References

    1. Schiffer CA, Anderson KC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, et al. Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1519–38. - PubMed
    1. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142:348–60. - PubMed
    1. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105:4106–14. - PMC - PubMed
    1. Legler TJ, Fischer I, Dittmann J, Simson G, Lynen R, Humpe A, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol. 1997;74:185–9. - PubMed
    1. Delaflor-Weiss E, Mintz PD. The evaluation and management of platelet refractoriness and alloimmunization. Transfus Med Rev. 2000;14:180–96. - PubMed